Viewing Opinion | StockChase
Gilead Sciences Inc. (GILD-Q) opinion on 2017-09-12

Last Price Recorded: 72.4400 on 2017-11-17

ON STOCKCHASE SINCE Dec 2008

biotechnology/pharmaceutical
COMMENT

Cameron Hurst
Gilead Sciences Inc. was $84.510 at time of opinion
Owned : Unknown

About 50% of its franchises are based in hepatitis C. You really have to be careful, because this franchise is slowing. They have 2 prospective years of negative earnings growth, which is a huge headwind. Value this on its long-term cash flows. There are 2 things to consider. 1.) How sustainable are they. If that continues, then you have a leg to stand on. 2.) If you have falling rates, that is good for valuation. The problem is, we are probably going to have flat to rising rates, and Pharma M&A is a bit of a dice roll. He doesn’t buy into the story, and would prefer the Spdr S&P Biotech ETF (XBI-N). You could be a little more conservative using the iShares D J Medical Devices ETF (IHI-N).

BEARISH on CANADIAN MARKET

All opinions for GILD-Q (196)

24 BUY
2 BUY on WEAKNESS
53 COMMENT
24 DON'T BUY
17 HOLD
1 PARTIAL BUY
2 PARTIAL SELL
24 PAST TOP PICK
7 SELL
1 STRONG BUY
30 TOP PICK
3 WAIT
4 WATCH
4 WEAK BUY
View All

More experts covering GILD-Q

SAVE
Add GILD-Q to Watch List

All opinions for GILD-Q (196)

24 BUY
2 BUY on WEAKNESS
53 COMMENT
24 DON'T BUY
17 HOLD
1 PARTIAL BUY
2 PARTIAL SELL
24 PAST TOP PICK
7 SELL
1 STRONG BUY
30 TOP PICK
3 WAIT
4 WATCH
4 WEAK BUY
View All

More experts covering GILD-Q

SAVE
Add GILD-Q to Watch List

No Comments.


You must be logged in to comment.

Successfully Saved Company